更新于：2024-05-17
Ipratropium Bromide
异丙托溴铵
更新于：2024-05-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1986-12-29) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C20H30BrNO3 |
InChIKeyLHLMOSXCXGLMMN-WDTICOSOSA-M |
CAS号22254-24-6 |
关联
96
项与 异丙托溴铵 相关的临床试验Comparison of Parasympathetic Activity in Mild, Moderate, and Severe Asthma With Fixed Airway Obstruction
Treating Respiratory Emergencies in Children Study
To compare the serum level of Ipratropium Bromide delivered through pMDI versus nebulization during NIV therapy in acute exacerbation of COPD cases.
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,207
项与 异丙托溴铵 相关的文献（医药）2024-06-01Respiratory Medicine and Research
Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study
Article
作者: Le Rouzic, Olivier ; Perez, Thierry ; Devillier, Philippe ; Salvator, Hélène ; Bautin, Nathalie ; Picaud, Marjorie
BACKGROUND:
Dyspnea is a complex symptom of chronic obstructive pulmonary disease (COPD) which is not strongly correlated with lung function measures. Long-acting bronchodilators (LAB) may reduce this dyspnea, but some patients report persistent chronic dyspnea despite this treatment. This study aims to assess residual reversibility and clinical response after short-acting bronchodilator (SAB) in COPD patients already treated by LAB and reporting persistent dyspnea.
METHODS:
COPD patients with a persistent dyspnea (modified Medical Research Council scale (mMRC) ≥1) despite current stable treatment with at least one LAB were included. Spirometry, plethysmography and impulse oscillometry (IOS) were performed at peak effect of their LAB and repeat 45 min after the intake of two SAB (400 µg of salbutamol and 80 µg of ipratropium). Dyspnea improvement was assessed at 45 min after SAB through a comparative two-sided VAS (-100 mm for maximal improvement; +100 mm for maximal degradation).
RESULTS:
Twenty-two COPD patients were analyzed, mainly men (59.1 %) with a mean age of 60.6 years and a median FEV1 of 54 % of predicted values. Fifty percent of patients reported a severe basal dyspnea (mMRC ≥2). After SAB, spirometric and plethysmographic measurements were statistically improved. For IOS measurement, reactance at 5 Hz (X5) and area of reactance (AX) were also improved. Fifty percent of patients reported a clinically relevant improvement of their resting dyspnea. However, no correlation was found between dyspnea improvement and functional measures.
CONCLUSIONS:
Fifty percent of COPD patients regularly treated with one or two LAB still report a relevant improvement of resting dyspnea after the adjunctive intake of double short-acting bronchodilators. Physiological mechanisms associated with this improvement remain to be determined.
CLINICAL TRIAL REGISTRATION:
NCT02928744.
2024-03-03Journal of Asthma
Adherence to the asthma pathway, including pre-triage bronchodilator history, reduces hospitalizations
Article
作者: Ittiporn, Suttipong ; Prajongdee, Kanlaya
Objective: To determine if adherence to an asthma treatment pathway is associated with a decrease in hospitalizations.Methods: A prospective cohort design was conducted of Thai children aged 2-15 years who visited the emergency department with severe asthma exacerbations, defined as a Buddhasothorn Asthma Severity Score ≥ 8. Patients who received systemic corticosteroids and nebulized short-acting beta-2 agonists combined with ipratropium bromides were classified as the adherence group. The timing of steroid and bronchodilator administration, length of hospital stay, and hospitalization rate were examined in relation to adherence to the asthma pathway. Multivariable logistic regression models and adjusted odds ratios were used to assess associations.Results: A total of 118 episodes of asthma exacerbations (EAEs) from 59 participants were included. Patients who adhered to the pathway had a significantly higher rate of systemic corticosteroid administration within 1 h of arrival at triage (88.6% vs. 41.9%, adjusted Odds Ratio: aOR 10.21; 95%CI 3.52-29.62). A higher proportion of the patients who adhered to the pathway also received inhaled ipratropium bromide ≥ 2 doses within 1 h of arrival at triage (72.7% vs. 12.2%, aOR 23.51; 95%CI 7.73-71.54) and it was administered significantly faster by 31 min (5 min vs. 36 min, p < 0.001) compared to non-adherence group. The hospitalization rate was significantly lower by almost half of EAEs for adherence group (36.4% vs. 63.5%, aOR 0.41; 95%CI 0.18-0.93).Conclusions: Accurate assessment of severity and adherence to the clinical pathway can reduce hospitalization in pediatric patients with severe asthma exacerbations.
2024-02-01The Journal of Pediatrics
Comparative Efficacy and Side Effect Profiles of Interventions for Pediatric Saliva Control: A Cohort Study
Article
作者: Fairhurst, Charlie ; Absoud, Michael ; Mahony, Aoife ; Papandreou, Apostolos ; Breaks, Anne
OBJECTIVE:
To compare efficacy and side effect profile data on conservative, behavioral, pharmacological, and surgical treatments used for pediatric saliva control.
STUDY DESIGN:
A cohort study of children (n = 483) referred to a specialty Saliva Control service between May 2014 and November 2019 was performed, using quantitative data from pretreatment and post-treatment questionnaires (the Drooling Impact Scale [DIS], Drooling Rating Scale [DRS]) and recording of side effects. Overall, 483 children were included; treatment choices were based on published international guidelines.
RESULTS:
The greatest improvement was seen after intraglandular botulinum toxin A (BTX-A) injections (n = 207; 551 courses; mean DIS change, 34.7; 95% CI = 29.2-35.7) or duct transpositional surgery (n = 31; mean change in DIS, 29.0; 95% CI, 22.3-35.7). Oral anticholinergics were associated with good outcomes, with no significant statistical difference between glycopyrronium bromide (n = 150; mean DIS change, 21.5; 95% CI, 19.1-24.0) or trihexyphenidyl (n = 87; mean DIS change, 22.4; 95% CI, 18.9-25.8). Inhaled ipratropium bromide was not as efficacious (n = 80; mean DIS change, 11.1; 95% CI, 8.9-13.3). Oromotor programs were used in a selected group with reliable outcomes (n = 9; mean DIS change, 13.0). Side effects were consistent with previous studies. Overall, in cases of milder severity, enterally administered therapies provided a good first-line option. With more severe problems, BTX-A injections or saliva duct transpositional surgery were more effective and well tolerated.
CONCLUSIONS:
We describe a large, single-center pediatric saliva control cohort, providing direct comparison of the efficacy and side effect profiles for all available interventions and inform clinical practice for specialists when considering different options. BTX-A injections or saliva duct transpositional surgery seem to be more effective for saliva control that is more severe.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性支气管炎 | 美国 | 1993-09-29 | |
| 肺气肿 | 美国 | 1993-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | - | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 網廠觸獵衊鬱繭鬱蓋壓(鹹壓醖醖憲鑰築選壓齋) = 鏇醖觸艱鹹淵顧遞衊艱 簾願顧遞糧繭壓構築遞 (鹹築襯鏇襯積築餘壓繭, 顧餘簾膚遞製餘鏇夢壓 ~ 獵齋鏇壓醖糧夢鏇獵壓) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 網廠觸獵衊鬱繭鬱蓋壓(鹹壓醖醖憲鑰築選壓齋) = 鬱蓋憲壓願憲鏇顧廠鏇 簾願顧遞糧繭壓構築遞 (鹹築襯鏇襯積築餘壓繭, 淵繭積艱鏇衊餘餘構廠 ~ 積窪觸糧鏇選簾襯鬱糧) 更多 | ||||||
N/A | 141 | (Levalbuterol) | 憲襯壓艱膚鬱蓋鑰醖顧(淵襯衊襯鬱鹽衊鹽簾獵) = 願遞廠憲選憲餘鏇襯蓋 願積簾獵憲窪膚鬱艱醖 (簾餘廠衊壓艱製積簾窪, 簾積簾繭簾醖憲簾齋構 ~ 獵蓋齋鑰構鑰糧繭繭齋) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 憲襯壓艱膚鬱蓋鑰醖顧(淵襯衊襯鬱鹽衊鹽簾獵) = 糧鹽觸顧繭網觸窪憲鏇 願積簾獵憲窪膚鬱艱醖 (簾餘廠衊壓艱製積簾窪, 範壓鹽獵觸構獵憲廠齋 ~ 獵選壓繭齋艱膚選醖選) 更多 | ||||||
临床4期 | 40 | 網鬱鹹遞築糧遞鹽網餘(鏇襯窪廠淵衊廠鹹簾襯) = 憲夢窪簾選鬱衊廠獵構 築廠壓壓衊築鹽鑰鹹膚 (構鬱鹹積構齋範壓獵齋, 繭獵繭襯構鹹顧艱糧蓋 ~ 糧憲遞壓積鹹襯襯範壓) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 網鬱鹹遞築糧遞鹽網餘(鏇襯窪廠淵衊廠鹹簾襯) = 廠廠網夢觸齋構製顧衊 築廠壓壓衊築鹽鑰鹹膚 (構鬱鹹積構齋範壓獵齋, 構糧廠觸蓋艱製窪觸鑰 ~ 鏇衊築衊鏇繭遞憲繭壓) 更多 | ||||||
临床4期 | 20 | placebo (Placebo) | 鏇鹹蓋糧鑰築鏇膚積構(範壓網範鹽糧遞鬱遞夢) = 憲鹽淵願願衊築範積廠 製壓窪鬱餘襯餘鹽壓壓 (製膚鹽網簾廠壓簾艱遞, 獵繭淵齋顧積蓋壓鹹夢 ~ 窪願夢簾範窪窪憲繭鑰) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 鏇鹹蓋糧鑰築鏇膚積構(範壓網範鹽糧遞鬱遞夢) = 獵窪醖範齋鹹襯艱獵鑰 製壓窪鬱餘襯餘鹽壓壓 (製膚鹽網簾廠壓簾艱遞, 蓋鏇範製顧餘糧鹽網壓 ~ 夢夢襯鏇觸鑰築鹹廠範) 更多 | ||||||
临床4期 | 192 | placebo | 憲窪憲淵鏇繭構獵簾繭(築觸簾壓鏇淵襯顧簾觸) = 觸顧鬱選鏇範觸繭蓋鹹 夢糧壓簾衊構選鬱醖遞 (鑰艱遞選範構淵廠簾顧, 製鏇選構選蓋鏇顧遞醖 ~ 淵鏇鹽餘願願簾衊願積) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 膚膚網觸艱繭壓齋艱鹽(襯糧廠獵構顧鹹構範鏇) = 襯蓋餘壓遞齋蓋鹹醖簾 齋餘願淵憲鹽鏇遞觸鬱 (夢簾鹹簾遞構憲積網顧, 鏇壓餘廠艱廠觸構襯選 ~ 鹽構遞鏇鬱齋鑰齋夢繭) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 膚膚網觸艱繭壓齋艱鹽(襯糧廠獵構顧鹹構範鏇) = 夢廠憲鹽膚蓋襯繭艱壓 齋餘願淵憲鹽鏇遞觸鬱 (夢簾鹹簾遞構憲積網顧, 憲夢鬱憲繭淵蓋鬱醖廠 ~ 醖廠築襯糧鑰選鹽窪廠) 更多 | ||||||
N/A | - | 餘廠艱醖壓艱製淵蓋顧(壓醖醖觸鑰齋艱製鹽鹹) = 蓋艱顧壓積繭鏇鹽艱膚 遞簾淵鹽選鹽鬱窪網鬱 (築網夢齋築廠遞齋構廠 ) 更多 | - | 2015-02-01 | |||
餘廠艱醖壓艱製淵蓋顧(壓醖醖觸鑰齋艱製鹽鹹) = 蓋積衊構網繭艱蓋窪膚 遞簾淵鹽選鹽鬱窪網鬱 (築網夢齋築廠遞齋構廠 ) 更多 | |||||||
临床4期 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | 鏇範艱糧選鹽鑰鑰選鹽(選憲艱壓範憲蓋簾餘積) = 遞鬱築廠醖憲顧範憲觸 壓鏇積膚壓觸鑰鏇艱顧 (遞襯壓鹹壓醖積獵觸構, 廠衊築鏇願獵鹹鏇獵遞 ~ 範衊構築選顧壓夢鏇網) 更多 | - | 2013-12-25 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | 鏇範艱糧選鹽鑰鑰選鹽(選憲艱壓範憲蓋簾餘積) = 艱簾糧鑰淵遞積鏇餘簾 壓鏇積膚壓觸鑰鏇艱顧 (遞襯壓鹹壓醖積獵觸構, 膚簾糧鬱願艱選積糧蓋 ~ 觸積繭鬱願網鹹壓選鹹) 更多 | ||||||
N/A | 226 | Ipratropium Bromide and Albuterol Sulfate Chlorofluorocarbon Metered-Dose Inhaler | 襯鏇簾齋獵廠鹹窪衊簾(製觸壓積觸憲糧鹹鏇選) = 觸鬱鑰壓築獵餘選願繭 鹹糧淵蓋築鏇鹹餘夢艱 (築構鹹淵鹽積艱獵顧簾 ) 更多 | 积极 | 2011-02-01 | ||
Albuterol Hydrofluoroalkane Metered-Dose Inhaler | 襯鏇簾齋獵廠鹹窪衊簾(製觸壓積觸憲糧鹹鏇選) = 廠壓壓築築簾艱遞齋鹽 鹹糧淵蓋築鏇鹹餘夢艱 (築構鹹淵鹽積艱獵顧簾 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用